Comparison of P2Y12 inhibitors for mortality and stent thrombosis in patients with acute coronary syndromes: Single center study of 10 793 consecutive ‘real-world’ patients

Comparison of P2Y12 inhibitors for mortality and stent thrombosis in patients with acute coronary syndromes: Single center study of 10 793 consecutive ‘real-world’ patients

Three oral platelet P2Y12 inhibitors, clopidogrel, prasugrel, and ticagrelor, are available for reducing the risk of cardiovascular death and stent thrombosis in patients with acute coronary syndromes (ACS). We sought to compare the efficacy of these antiplatelet drugs in contemporary practice. Data...

Full description

Bibliographic Details
Main Authors: Rebecca Gosling, Momina Yazdani, Yasir Parviz, Ian R Hall, Ever D. Grech, Julian P Gunn, Robert F. Storey, Javaid Iqbal
Format: Article
Language:English
Published: Taylor & Francis Group 2017-11-01
Series:Platelets
Subjects:
acute coronary syndromes
clopidogrel
percutaneous coronary intervention
prasugrel
stent thrombosis
ticagrelor
Online Access:http://dx.doi.org/10.1080/09537104.2017.1280601

Internet

http://dx.doi.org/10.1080/09537104.2017.1280601

Similar Items